“Melan-A (A103) highlights the invasion in this melanoma.” Image Source.

MART-1 (melanoma antigen recognized by T cells 1) is a “widely shared melanoma antigen recognized by the T lymphocytes of patients with established malignancy.”

MART-1 is one of the oldest identified tumor antigens and is a protein found on normal melanocytes in the skin and retina. It is also found in most melanomas, cancers that originate in melanocytes.

Normal individuals seem to have a significant number of MART-1-reactive T cells. MART-1 is targeted by tumor-infiltrating lymphocytes (TIL) and is thought to be naturally recognized by the immune system.

Read more about the discovery of the MART-1 antigen in this 1994 research by Yutaka Kawakami, et al. and the independent, concurrent discovery of the same antigen, referred to as Melan-A by Coulie et al.

MART-1 Vaccinations

Antibodies against MART-1 are used as markers to diagnose melanoma, and the discovery of the MART-1 antigen itself opened doors to new immunotherapy development for patients with melanoma.

Vaccines utilizing the MART-1 antigen are being investigated for their ability to boost the immune system’s cytotoxic T cell response to malignant melanoma cells.

There are dozens of completed or in-progress clinical trials studying the impacts of MART-1, a few of which include:

Anti-MART-1 T Cells for Immunotherapy Research

To aid in the advancement of MART-1 immunotherapy research, we have developed a T cell line specific to the MART-1 antigen.

Our anti-MART-1 T cell line is specific to the sequence AAGIGILTV (residues 27–35) that binds to HLA-A*02:01. The analog peptide ELAGIGILTV (residues 26–35) can also be used for improved binding to HLA-A*02:01.

Use our anti-MART-1 T cell line to study the recognition and death of melanoma cells.

Leave a Reply

Your email address will not be published. Required fields are marked *

Post comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.